Tracking Solid-Dosage Equipment - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tracking Solid-Dosage Equipment
Tablets and capsules are mainstay product forms, so what are the spending and innovation trends for solid-dosage manufacturing equipment and machinery?


Pharmaceutical Technology
Volume 34, Issue 4, pp. 58-62

High-containment or high-potency manufacturing . The survey also examined the extent of spending in specialized areas such as high-containment or high-potency manufacturing for all product forms. The survey showed that 25.3% of respondents increased their spending on equipment and machinery used for high-containment or high-potency finished-drug product manufacturing, 55.8% kept it the same, and 18.9% decreased spending in this area.

Planned expenditures for 2010 are commensurate with 2009 levels. The survey showed that 24.6% of respondents plan to increase their spending on equipment and machinery used for high-containment or high-potency finished-drug product manufacturing, 52.3% kept it the same, and 18.9% decreased spending in this area.

Continuous processing . One area for more robust spending was machinery and equipment used in continuous processing for finished-drug products. Although the pharmaceutical industry primarily uses batch manufacturing, certain functions in solid-dosage manufacturing may operate in a semicontinuous mode, and in general, there is ongoing interest in continuous processing under a quality-by-design paradigm. The survey showed that 30.4% of respondents plan to increase their expenditures on equipment and machinery used in continuous processing in 2010, 53.4% plan to keep it the same, and 16% plan to decrease it. The number of respondents planning to increase spending in this area (30.4%) is up significantly from 2009, when only 19.1% of survey respondents increased spending for equipment used in continuous processing.Approximately two-thirds (62.8%) spent the same, and 18.1% decreased their expenditures.

Innovation trends

The survey examined to what extent companies were involved with specialized manufacturing or newer manufacturing technologies. Despite the uptick in spending for equipment and machinery used in continuous processing of finished-drug products, the majority of respondents (61.3%) said they do not use such equipment in their manufacturing process.

Survey respondents, however, were largely favorable of the level of product innovation for equipment and machinery used in continuous processing for finished-drug products. Almost two-thirds (62.5%) of respondents said that the level of product innovation in this area has been "high" and "medium" during the past two years (2008 and 2009). Thirty-nine percent said there has been "little or no" innovation in continuous-processing equipment for finished-drug product manufacturing during the past two years.

Respondents were fairly satisfied with the level of product innovation in solid-dosage manufacturing overall, but were less satisfied with the level of innovation for specific equipment types. More than half (58.3%) of respondents said that the level of product innovation in solid-dosage manufacturing equipment was "high" or "medium" during the past two years. Nearly one-quarter (24.5%) said it was "low," and 17.2% said there has been no innovation during the past two years.

Respondents were slightly less sanguine about advances in tablet presses and capsule-filling machines. Only about half (52.4%) of respondents said that product innovation of these equipment types was "high" or "medium" during the past two years. Only 13.6% of respondents characterized innovation for tablet presses or capsule-filling machines as "high," and 38.8% ranked it as "medium." Almost half (47.6%) of respondents said there has been "little or no" innovation in tablet presses or capsule-filling machines during the past two years (2008 and 2009). The survey showed that 28.6% of respondents said there has been "little" innovation, and 19.0% said there has been "no" innovation.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here